BRPI0108923B8 - elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina - Google Patents
elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxinaInfo
- Publication number
- BRPI0108923B8 BRPI0108923B8 BR0108923A BR0108923A BRPI0108923B8 BR PI0108923 B8 BRPI0108923 B8 BR PI0108923B8 BR 0108923 A BR0108923 A BR 0108923A BR 0108923 A BR0108923 A BR 0108923A BR PI0108923 B8 BRPI0108923 B8 BR PI0108923B8
- Authority
- BR
- Brazil
- Prior art keywords
- specific binding
- binding member
- eotaxin
- antibody
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18724600P | 2000-03-03 | 2000-03-03 | |
PCT/GB2001/000927 WO2001066754A1 (en) | 2000-03-03 | 2001-03-02 | Human antibodies against eotaxin and their use |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0108923A BR0108923A (pt) | 2003-04-22 |
BRPI0108923B1 BRPI0108923B1 (pt) | 2018-11-13 |
BRPI0108923B8 true BRPI0108923B8 (pt) | 2021-05-25 |
Family
ID=22688187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0108923A BRPI0108923B8 (pt) | 2000-03-03 | 2001-03-02 | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
Country Status (14)
Country | Link |
---|---|
US (6) | US7323311B2 (pt) |
EP (1) | EP1259615B1 (pt) |
JP (1) | JP5198704B2 (pt) |
AT (1) | ATE414151T1 (pt) |
AU (1) | AU778392B2 (pt) |
BR (1) | BRPI0108923B8 (pt) |
CA (1) | CA2401342C (pt) |
DE (1) | DE60136527D1 (pt) |
GB (1) | GB2361704C (pt) |
IL (2) | IL151499A0 (pt) |
MX (1) | MXPA02008472A (pt) |
NO (1) | NO20024179L (pt) |
NZ (1) | NZ521182A (pt) |
WO (1) | WO2001066754A1 (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE414151T1 (de) | 2000-03-03 | 2008-11-15 | Cambridge Antibody Tech | Antikörper gegen eotaxin und deren verwendung |
JP2005509412A (ja) | 2001-08-23 | 2005-04-14 | アールエスアール リミテッド | チロトロフィン(tsh)受容体の抗原決定領域、その使用およびその抗体 |
JP2007525436A (ja) * | 2003-03-24 | 2007-09-06 | マーシア・ファーマ・インコーポレイテッド | 炎症症状を処置および予防するための方法および組成物 |
GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
CN104151427B (zh) | 2005-02-08 | 2017-09-08 | 根茨美公司 | 针对TGFβ的抗体 |
US20070099239A1 (en) * | 2005-06-24 | 2007-05-03 | Raymond Tabibiazar | Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease |
SI1942939T2 (sl) | 2005-09-30 | 2021-11-30 | Medimmune Limited | Sestavek protitelesa proti interlevkinu-13 |
DK1999152T3 (da) | 2006-03-27 | 2013-01-14 | Medimmune Ltd | Bindende element til gm-csf-receptor |
RU2016142225A (ru) | 2009-05-13 | 2018-12-18 | Джензим Корпорейшн | Иммуноглобулины к cd52 человека |
US8176867B2 (en) | 2009-05-28 | 2012-05-15 | Richard J. A. Gayton | Watercraft immobilizing system |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
AU2011329647B2 (en) | 2010-11-19 | 2015-10-22 | Eisai R&D Management Co., Ltd. | Neutralizing anti-CCL20 antibodies |
US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US20140271666A1 (en) * | 2013-03-14 | 2014-09-18 | Immune Pharmaceuticals Ltd. | Use of anti-eotaxin antibodies for treating inflammatory bowel disease |
AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
DK3050574T3 (da) | 2015-01-28 | 2020-01-20 | Univ Bordeaux | Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom |
KR102261618B1 (ko) | 2015-03-31 | 2021-06-04 | 메디뮨 리미티드 | 신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법 |
MX2018008939A (es) | 2016-01-22 | 2019-08-21 | Merck Sharp & Dohme | Anticuerpos anti-factor de la coagulacion xi. |
EP4000632A1 (en) | 2016-06-02 | 2022-05-25 | MedImmune Limited | Antibodies to alpha-synuclein and uses thereof |
WO2017212488A1 (en) * | 2016-06-06 | 2017-12-14 | Hadasit Medical Research Service And Development Ltd. | Anti-eotaxin for immunoprotection and hepatoprotection |
MY201852A (en) | 2016-06-14 | 2024-03-20 | Merck Sharp & Dohme Llc | Anti-coagulation factor xi antibodies |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8925590D0 (en) | 1989-11-13 | 1990-01-04 | Central Blood Lab Authority | Monoclonal antibodies |
EP0523949B1 (en) * | 1991-07-15 | 2003-06-25 | The Wellcome Foundation Limited | Production of antibodies |
IL103758A (en) | 1991-12-13 | 1998-07-15 | Akzo Nv | Cancer-specific monoclonal antibodies |
DE69434878T3 (de) * | 1993-09-14 | 2014-07-17 | Imperial Innovations Ltd. | Eotaxin = eosinophil chemotaktisches cytokin |
US6403782B1 (en) | 1995-06-22 | 2002-06-11 | President And Fellows Of Harvard College | Nucleic acid encoding eotaxin |
US7265201B1 (en) | 1995-06-23 | 2007-09-04 | Millennium Pharmaceuticals, Inc. | Human chemotactic cytokine |
AU7097696A (en) * | 1995-10-05 | 1997-04-28 | Shionogi & Co., Ltd. | Novel human cc chemokine |
WO1999010534A1 (en) | 1997-08-22 | 1999-03-04 | Center For Blood Research, Inc. | Diagnosis and treatment of diseases with eotaxin and antagonists and agonists thereof |
GB9809951D0 (en) * | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
WO1999066951A2 (en) * | 1998-06-22 | 1999-12-29 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
MXPA02001911A (es) | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
ATE414151T1 (de) | 2000-03-03 | 2008-11-15 | Cambridge Antibody Tech | Antikörper gegen eotaxin und deren verwendung |
US6946546B2 (en) | 2000-03-06 | 2005-09-20 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin |
GB0016138D0 (en) | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
-
2001
- 2001-03-02 AT AT01907990T patent/ATE414151T1/de not_active IP Right Cessation
- 2001-03-02 BR BR0108923A patent/BRPI0108923B8/pt not_active IP Right Cessation
- 2001-03-02 EP EP01907990A patent/EP1259615B1/en not_active Expired - Lifetime
- 2001-03-02 AU AU35852/01A patent/AU778392B2/en not_active Expired
- 2001-03-02 WO PCT/GB2001/000927 patent/WO2001066754A1/en active IP Right Grant
- 2001-03-02 NZ NZ521182A patent/NZ521182A/en not_active IP Right Cessation
- 2001-03-02 JP JP2001565908A patent/JP5198704B2/ja not_active Expired - Lifetime
- 2001-03-02 IL IL15149901A patent/IL151499A0/xx unknown
- 2001-03-02 GB GB0105237A patent/GB2361704C/en not_active Expired - Lifetime
- 2001-03-02 DE DE60136527T patent/DE60136527D1/de not_active Expired - Lifetime
- 2001-03-02 US US10/220,418 patent/US7323311B2/en not_active Expired - Lifetime
- 2001-03-02 MX MXPA02008472A patent/MXPA02008472A/es unknown
- 2001-03-02 CA CA2401342A patent/CA2401342C/en not_active Expired - Lifetime
-
2002
- 2002-08-27 IL IL151499A patent/IL151499A/en active IP Right Grant
- 2002-09-02 NO NO20024179A patent/NO20024179L/no not_active Application Discontinuation
-
2007
- 2007-12-17 US US11/958,210 patent/US8067564B2/en not_active Expired - Fee Related
-
2011
- 2011-10-19 US US13/277,132 patent/US8715961B2/en not_active Expired - Lifetime
-
2014
- 2014-03-24 US US14/223,561 patent/US9284589B2/en not_active Expired - Fee Related
-
2016
- 2016-02-03 US US15/014,945 patent/US10577413B2/en not_active Expired - Fee Related
-
2020
- 2020-09-03 US US17/011,379 patent/US20210277103A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0108923B8 (pt) | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina | |
HRP20160270T1 (hr) | Monoklonska antitijela protiv glipikana-3 | |
HRP20161338T1 (hr) | Limfocitni antigen | |
BRPI0611414B8 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao tweak humano, composição farmacêutica e seus usos | |
CY1115671T1 (el) | Θεραπευτικη χρηση αντισωματων anti-cs1 | |
BRPI0407833A (pt) | anticorpo monoclonal humano isolado, e, método de tratar ou prevenir um distúrbio | |
HRP20060033A2 (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
PT2305715T (pt) | Anticorpo monoclonal para a proteína de ligação a osteoprotegerina | |
DK1425389T3 (da) | Interleukin-15-(IL-15)-specifikke humane antistoffer | |
DE60130538D1 (de) | Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung | |
BRPI0611984A2 (pt) | uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo | |
DE60031279D1 (de) | Humane monoklonale antikörper gegen prostata spezifisches membranantigen | |
BRPI0214137B8 (pt) | anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo | |
ATE482722T1 (de) | Therapeutische verwendung von anti-cs1- antikörpern | |
BRPI0513078C1 (pt) | anticorpo igg que se liga a il-17 humana e composição líquida | |
DK1504035T3 (da) | Antistoffer, der er specifikke for human CD22, og deres terapeutiske og diagnostiske anvendelser | |
DK3284753T3 (da) | Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose | |
BRPI0614040B8 (pt) | anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo | |
NO20083053L (no) | Humane monoklonale antistoffer mot O8E | |
BR0306808A (pt) | Anticorpos monoclonais humanos contra cd30 | |
ECSP024402A (es) | Anticuerpos para mcp-1 humana | |
BR0207068A (pt) | Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus | |
WO2004046306A3 (en) | Fully human antibody fab fragments with human interferon-gamma neutralizing activity | |
ATE435239T1 (de) | Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen | |
WO2002059154A3 (en) | Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 15/13 , C12N 15/62 , C12N 5/10 , C07K 16/24 Ipc: C07K 16/24 (2006.01), C12N 15/19 (2006.01), C12N 1 |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/11/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B25D | Requested change of name of applicant approved |
Owner name: MEDIMMUNE LIMITED (GB) |
|
B25G | Requested change of headquarter approved |
Owner name: MEDIMMUNE LIMITED (GB) |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/03/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 02/03/2021 |